word,tfidf
disease,0.2645178501462773
transplantation,0.2441703232119483
cell,0.23908344147836605
bd,0.21069891677568103
cells,0.16278021547463217
stem,0.15260645200746767
anti,0.15260645200746767
versus,0.14751957027388543
uveitis,0.13734580680672093
graft,0.13734580680672093
hematopoietic,0.13225892507313866
host,0.1271720433395564
haplo,0.1271720433395564
donor,0.11191139813880963
survival,0.11191139813880963
use,0.10250217572870969
unrelated,0.10173763467164512
pharmacodynamic,0.0959412679951483
severe,0.0915638712044806
rituximab,0.0906543246604106
efficacy,0.08541847977392474
free,0.08541847977392474
randomized,0.08541847977392474
vasculitis,0.08139010773731609
reported,0.08139010773731609
antigen,0.07972391445566308
matched,0.07402934913740143
tumor,0.07402934913740143
refractory,0.07121634427015158
cd,0.07035692986310875
sct,0.0683347838191398
leukocyte,0.0683347838191398
mismatched,0.06685353528898197
associated,0.06612946253656933
tnf,0.06612946253656933
myelofibrosis,0.06593041793484407
controlled,0.06503225091438128
mud,0.06396084533009887
identical,0.06264021850087814
mortality,0.06264021850087814
major,0.06264021850087814
transplant,0.06104258080298707
human,0.06104258080298707
ptcy,0.0578064452572278
combination,0.0578064452572278
prospective,0.0578064452572278
ric,0.057689115692988555
hypothesis,0.05756476079708897
effective,0.05756476079708897
biologics,0.05730303024769884
higher,0.0569456531826165
acute,0.05595569906940481
relapse,0.05595569906940481
10,0.05595569906940481
cryoglobulinemia,0.05595569906940481
immune,0.05595569906940481
outcome,0.05595569906940481
antibody,0.051251087864354845
ks,0.051251087864354845
donors,0.05116867626407909
regimen,0.05116867626407909
role,0.05116867626407909
transplanted,0.05116867626407909
systemic,0.05086881733582256
high,0.05086881733582256
remission,0.05086881733582256
post,0.05086881733582256
recently,0.05058063960007433
l1,0.05058063960007433
cases,0.05058063960007433
european,0.05058063960007433
improved,0.04944781345113305
frequent,0.04944781345113305
head,0.04944781345113305
baff,0.0477525252064157
blindness,0.0477525252064157
overall,0.0457819356022403
group,0.0457819356022403
outcomes,0.045556522546093194
stromal,0.045556522546093194
infectious,0.045556522546093194
aiec,0.045556522546093194
mesenchymal,0.045556522546093194
better,0.044772591731069206
immunosuppressive,0.044772591731069206
thymoglobulin,0.044772591731069206
expression,0.044772591731069206
comparing,0.044772591731069206
strong,0.043354833942920855
monoclonal,0.043354833942920855
rationale,0.04120651120927754
significantly,0.04120651120927754
blockade,0.04120651120927754
morbidity,0.04120651120927754
dramatically,0.04120651120927754
phase,0.04069505386865804
safety,0.04069505386865804
50,0.04069505386865804
evidence,0.04069505386865804
involvement,0.04069505386865804
reduce,0.03986195722783154
manifestations,0.03986195722783154
international,0.03986195722783154
approach,0.03986195722783154
shown,0.038376507198059316
laherparepvec,0.038376507198059316
allo,0.038376507198059316
talimogene,0.038376507198059316
lower,0.038376507198059316
recent,0.038376507198059316
retrospective,0.03820202016513256
depletion,0.03820202016513256
saa,0.03820202016513256
addressing,0.03820202016513256
kroger,0.03820202016513256
tcz,0.03820202016513256
il6,0.03820202016513256
antagonists,0.03820202016513256
efficient,0.036129028285767376
atlg,0.036129028285767376
virus,0.036129028285767376
agents,0.036129028285767376
70,0.03560817213507579
40,0.03560817213507579
treatments,0.03560817213507579
response,0.03560817213507579
year,0.03560817213507579
chronic,0.03560817213507579
posterior,0.03560817213507579
viral,0.0341673919095699
cyclophosphamide,0.0341673919095699
antibodies,0.0341673919095699
adalimumab,0.0341673919095699
mds,0.0341673919095699
therapeutic,0.0341673919095699
inflammation,0.0341673919095699
term,0.0341673919095699
threatening,0.0341673919095699
cd38,0.032965208967422034
young,0.032965208967422034
2019,0.032965208967422034
intestinal,0.032965208967422034
increasing,0.032965208967422034
properties,0.032965208967422034
league,0.032965208967422034
rheumatism,0.032965208967422034
highly,0.032965208967422034
curative,0.032965208967422034
repeated,0.031980422665049434
reduced,0.031980422665049434
fludarabine,0.031980422665049434
induced,0.031980422665049434
aml,0.031980422665049434
niu,0.031980422665049434
intermediate,0.031980422665049434
correlated,0.031980422665049434
activity,0.030521290401493536
conditioning,0.030521290401493536
met,0.030521290401493536
best,0.030521290401493536
increased,0.030521290401493536
therapy,0.030521290401493536
poor,0.030521290401493536
ocular,0.030521290401493536
20,0.030521290401493536
resistant,0.0289032226286139
strategy,0.0289032226286139
prevent,0.0289032226286139
question,0.0289032226286139
dependency,0.0289032226286139
despite,0.0289032226286139
approved,0.0289032226286139
sight,0.0289032226286139
fluid,0.0289032226286139
immunosuppressants,0.0289032226286139
induction,0.0289032226286139
presenting,0.02865151512384942
elt,0.02865151512384942
effector,0.02865151512384942
increases,0.02865151512384942
blys,0.02865151512384942
ist,0.02865151512384942
cbt,0.02865151512384942
fda,0.02865151512384942
mice,0.02865151512384942
deletion,0.02865151512384942
firm,0.02865151512384942
grafts,0.02865151512384942
significant,0.02847282659130825
incidence,0.02847282659130825
able,0.02847282659130825
effects,0.02847282659130825
abo,0.025584338132039544
mismatch,0.025584338132039544
mofetil,0.025584338132039544
demonstrate,0.025584338132039544
treosulfan,0.025584338132039544
evaluate,0.025584338132039544
sibling,0.025584338132039544
setting,0.025584338132039544
mycophenolate,0.025584338132039544
directly,0.025584338132039544
age,0.025584338132039544
currently,0.025584338132039544
management,0.02543440866791128
60,0.02543440866791128
level,0.02543440866791128
observed,0.02543440866791128
capmatinib,0.02543440866791128
early,0.02543440866791128
data,0.02543440866791128
infusion,0.02543440866791128
main,0.02543440866791128
ii,0.02543440866791128
steroids,0.02543440866791128
second,0.02543440866791128
benefit,0.02543440866791128
cord,0.024723906725566524
replication,0.024723906725566524
2009,0.024723906725566524
propose,0.024723906725566524
spinal,0.024723906725566524
inhibitors,0.024723906725566524
pd1,0.024723906725566524
metabolism,0.024723906725566524
biologic,0.024723906725566524
demonstrated,0.024723906725566524
achieve,0.024723906725566524
leading,0.024723906725566524
cerebro,0.024723906725566524
study,0.024723906725566524
tumors,0.024723906725566524
agency,0.024723906725566524
suggest,0.024723906725566524
experimental,0.022778261273046597
neurological,0.022778261273046597
cancer,0.022778261273046597
population,0.022778261273046597
long,0.022778261273046597
effect,0.022778261273046597
inflammatory,0.022778261273046597
type,0.022778261273046597
good,0.022778261273046597
serum,0.022778261273046597
antibiotic,0.022778261273046597
iii,0.022778261273046597
vascular,0.022778261273046597
allogeneic,0.022778261273046597
line,0.022778261273046597
compared,0.022778261273046597
anemia,0.022778261273046597
terms,0.022778261273046597
sclerosis,0.022778261273046597
2014,0.022778261273046597
reduction,0.022778261273046597
acquired,0.021677416971460427
2015,0.021677416971460427
updated,0.021677416971460427
leukemia,0.021677416971460427
superior,0.021677416971460427
checkpoint,0.021677416971460427
haploidentical,0.021677416971460427
carcinoma,0.021677416971460427
alternative,0.021677416971460427
derived,0.021677416971460427
targeting,0.021677416971460427
inhibition,0.021677416971460427
important,0.021677416971460427
mainly,0.021677416971460427
medicines,0.021677416971460427
antidepressant,0.021677416971460427
adults,0.021677416971460427
rejection,0.021677416971460427
registry,0.021677416971460427
option,0.021677416971460427
12,0.02034752693432902
optimal,0.02034752693432902
red,0.02034752693432902
treated,0.02034752693432902
complete,0.02034752693432902
primary,0.02034752693432902
behcets,0.02034752693432902
days,0.02034752693432902
infections,0.02034752693432902
increase,0.02034752693432902
active,0.02034752693432902
life,0.02034752693432902
rate,0.02034752693432902
grade,0.02034752693432902
event,0.02034752693432902
depression,0.019188253599029658
allowing,0.019188253599029658
phenotypic,0.019188253599029658
improvement,0.019188253599029658
aa,0.019188253599029658
ref,0.019188253599029658
potentially,0.019188253599029658
rapidly,0.019188253599029658
grfs,0.019188253599029658
recipient,0.019188253599029658
disorders,0.019188253599029658
infliximab,0.019188253599029658
responsible,0.019188253599029658
possible,0.019188253599029658
especially,0.019188253599029658
presentation,0.01910101008256628
retina,0.01910101008256628
encouraging,0.01910101008256628
isohemagglutinins,0.01910101008256628
unknown,0.01910101008256628
advocated,0.01910101008256628
jak,0.01910101008256628
allele,0.01910101008256628
sustainable,0.01910101008256628
gm,0.01910101008256628
mucocutaneous,0.01910101008256628
panuveitis,0.01910101008256628
proinflammatory,0.01910101008256628
compounds,0.01910101008256628
remain,0.01910101008256628
focus,0.01910101008256628
yielded,0.01910101008256628
novel,0.01910101008256628
favorable,0.01910101008256628
bregante,0.01910101008256628
guarantees,0.01910101008256628
literature,0.01910101008256628
little,0.01910101008256628
ruxolitinib,0.01910101008256628
robin,0.01910101008256628
pathway,0.01910101008256628
mcc,0.01910101008256628
immunity,0.01910101008256628
innovative,0.01910101008256628
biotherapies,0.01910101008256628
hepatocellular,0.01910101008256628
axis,0.01910101008256628
hypothesize,0.01910101008256628
designed,0.01910101008256628
raising,0.01910101008256628
developing,0.01910101008256628
supports,0.01910101008256628
transfusional,0.01910101008256628
raj,0.01910101008256628
costs,0.01708369595478495
received,0.01708369595478495
pembrolizumab,0.01708369595478495
considering,0.01708369595478495
sparing,0.01708369595478495
body,0.01708369595478495
belimumab,0.01708369595478495
2016,0.01708369595478495
need,0.01708369595478495
adult,0.01708369595478495
45,0.01708369595478495
transfusions,0.01708369595478495
classification,0.01708369595478495
oncolytic,0.016482604483711017
failed,0.016482604483711017
older,0.016482604483711017
oesogastric,0.016482604483711017
remains,0.016482604483711017
vitro,0.016482604483711017
expert,0.016482604483711017
prognosis,0.016482604483711017
vessels,0.016482604483711017
2010,0.016482604483711017
ci,0.016482604483711017
confirm,0.016482604483711017
reducing,0.016482604483711017
flu,0.016482604483711017
zone,0.016482604483711017
nature,0.016482604483711017
allogenic,0.016482604483711017
alpha,0.016482604483711017
marginal,0.016482604483711017
sufficient,0.016482604483711017
published,0.016482604483711017
needed,0.016482604483711017
coli,0.016482604483711017
receptor,0.016482604483711017
proposes,0.016482604483711017
tomosynthesis,0.016482604483711017
selective,0.016482604483711017
hope,0.016482604483711017
prolonged,0.016482604483711017
il,0.016482604483711017
majority,0.016482604483711017
promising,0.016482604483711017
microbiota,0.016482604483711017
provides,0.016482604483711017
healthy,0.016482604483711017
attacks,0.016482604483711017
preventing,0.016482604483711017
intraocular,0.016482604483711017
successfully,0.016482604483711017
submitted,0.016482604483711017
categories,0.016482604483711017
umbilical,0.016482604483711017
discussed,0.016482604483711017
venous,0.016482604483711017
failures,0.016482604483711017
issues,0.016482604483711017
carrying,0.016482604483711017
replete,0.016482604483711017
goal,0.016482604483711017
activated,0.016482604483711017
eye,0.015260645200746768
value,0.015260645200746768
concentration,0.015260645200746768
available,0.015260645200746768
infection,0.015260645200746768
arm,0.015260645200746768
plasma,0.015260645200746768
information,0.015260645200746768
steroid,0.015260645200746768
model,0.015260645200746768
secondary,0.015260645200746768
rates,0.015260645200746768
prca,0.015260645200746768
retinal,0.015260645200746768
evolution,0.015260645200746768
syndrome,0.015260645200746768
recommendations,0.015260645200746768
following,0.015260645200746768
france,0.015260645200746768
administration,0.015260645200746768
vessel,0.015260645200746768
30,0.015260645200746768
optimized,0.01445161131430695
pain,0.01445161131430695
enzymes,0.01445161131430695
functional,0.01445161131430695
median,0.01445161131430695
maintain,0.01445161131430695
myeloablative,0.01445161131430695
2017,0.01445161131430695
observational,0.01445161131430695
2011,0.01445161131430695
diagnostic,0.01445161131430695
hsv,0.01445161131430695
arterial,0.01445161131430695
mammography,0.01445161131430695
malignancies,0.01445161131430695
tissue,0.01445161131430695
colonized,0.01445161131430695
prevention,0.01445161131430695
prescription,0.01445161131430695
lymphoma,0.01445161131430695
targets,0.01445161131430695
plus,0.01445161131430695
bacteria,0.01445161131430695
intensity,0.01445161131430695
drugs,0.01445161131430695
cd20,0.01445161131430695
proven,0.01445161131430695
development,0.01445161131430695
identify,0.01445161131430695
idiopathic,0.01445161131430695
gov,0.01445161131430695
immunosuppressant,0.01445161131430695
improve,0.01445161131430695
controls,0.01445161131430695
prognostic,0.01445161131430695
compare,0.01445161131430695
initiated,0.01445161131430695
invasive,0.01445161131430695
interferon,0.01445161131430695
immunomodulatory,0.01445161131430695
psychiatric,0.01445161131430695
treat,0.012792169066019772
www,0.012792169066019772
2008,0.012792169066019772
uncontrolled,0.012792169066019772
reconstitution,0.012792169066019772
autoimmune,0.012792169066019772
addition,0.012792169066019772
models,0.012792169066019772
aged,0.012792169066019772
aims,0.012792169066019772
aplastic,0.012792169066019772
team,0.012792169066019772
fully,0.012792169066019772
biomarkers,0.012792169066019772
involving,0.012792169066019772
choice,0.012792169066019772
lupus,0.012792169066019772
chemotherapy,0.012792169066019772
recommendation,0.012792169066019772
elderly,0.012792169066019772
diseases,0.012792169066019772
profile,0.012792169066019772
endemic,0.012792169066019772
sarcoma,0.012792169066019772
http,0.012792169066019772
prophylaxis,0.012792169066019772
95,0.012792169066019772
rapid,0.012792169066019772
65,0.012792169066019772
usually,0.012792169066019772
80,0.011389130636523298
11,0.011389130636523298
obtain,0.011389130636523298
delayed,0.011389130636523298
absence,0.011389130636523298
different,0.011389130636523298
factors,0.011389130636523298
overload,0.011389130636523298
tolerance,0.011389130636523298
antibiotics,0.011389130636523298
assess,0.011389130636523298
limited,0.011389130636523298
iron,0.011389130636523298
loss,0.011389130636523298
endpoint,0.011389130636523298
historical,0.011389130636523298
engraftment,0.011389130636523298
tocilizumab,0.011389130636523298
isatuximab,0.011389130636523298
marrow,0.011389130636523298
visual,0.011389130636523298
2013,0.011389130636523298
infusions,0.011389130636523298
confirmed,0.011389130636523298
size,0.011389130636523298
source,0.011389130636523298
standardization,0.011389130636523298
spartalizumab,0.011389130636523298
inhibitor,0.011389130636523298
requiring,0.011389130636523298
kaposi,0.011389130636523298
comparison,0.011389130636523298
double,0.011389130636523298
previous,0.011389130636523298
family,0.011389130636523298
nomenclature,0.011389130636523298
usual,0.011389130636523298
2012,0.011389130636523298
cov2,0.011389130636523298
exposed,0.011389130636523298
ileal,0.011389130636523298
weeks,0.01017376346716451
assessed,0.01017376346716451
sars,0.01017376346716451
19,0.01017376346716451
period,0.01017376346716451
anterior,0.01017376346716451
milligrams,0.01017376346716451
resolution,0.01017376346716451
toxicity,0.01017376346716451
pre,0.01017376346716451
levels,0.01017376346716451
test,0.01017376346716451
kilograms,0.01017376346716451
events,0.01017376346716451
peripheral,0.01017376346716451
potential,0.01017376346716451
complications,0.01017376346716451
considered,0.01017376346716451
death,0.01017376346716451
probability,0.01017376346716451
procedure,0.01017376346716451
severity,0.01017376346716451
vitreous,0.01017376346716451
ongoing,0.01017376346716451
failure,0.01017376346716451
needing,0.00955050504128314
nct02795429,0.00955050504128314
nct02213705,0.00955050504128314
nct01795677,0.00955050504128314
obvious,0.00955050504128314
nowadays,0.00955050504128314
nonsteroidal,0.00955050504128314
favour,0.00955050504128314
favourably,0.00955050504128314
redness,0.00955050504128314
exposing,0.00955050504128314
ophthalmic,0.00955050504128314
unpublished,0.00955050504128314
unresponsive,0.00955050504128314
urgent,0.00955050504128314
urgently,0.00955050504128314
uveal,0.00955050504128314
adherent,0.00955050504128314
gender,0.00955050504128314
disappointing,0.00955050504128314
vigorous,0.00955050504128314
generated,0.00955050504128314
genes,0.00955050504128314
genova,0.00955050504128314
globulins,0.00955050504128314
signal,0.00955050504128314
creates,0.00955050504128314
crucial,0.00955050504128314
contrasting,0.00955050504128314
produce,0.00955050504128314
produced,0.00955050504128314
producing,0.00955050504128314
proliferative,0.00955050504128314
immunosuppressors,0.00955050504128314
impairing,0.00955050504128314
impressive,0.00955050504128314
improvements,0.00955050504128314
ifx,0.00955050504128314
senescence,0.00955050504128314
sequence,0.00955050504128314
series,0.00955050504128314
display,0.00955050504128314
corticoids,0.00955050504128314
concept,0.00955050504128314
concluded,0.00955050504128314
confirming,0.00955050504128314
consequently,0.00955050504128314
sources,0.00955050504128314
cryoglobulinemic,0.00955050504128314
cyclophophamide,0.00955050504128314
simplex,0.00955050504128314
sjogrens,0.00955050504128314
solution,0.00955050504128314
interfering,0.00955050504128314
specie,0.00955050504128314
specificities,0.00955050504128314
spectrum,0.00955050504128314
stability,0.00955050504128314
staining,0.00955050504128314
stimulating,0.00955050504128314
innate,0.00955050504128314
intact,0.00955050504128314
individualized,0.00955050504128314
induces,0.00955050504128314
infiltrating,0.00955050504128314
drb1,0.00955050504128314
dysregulated,0.00955050504128314
recognition,0.00955050504128314
follicular,0.00955050504128314
food,0.00955050504128314
represent,0.00955050504128314
represents,0.00955050504128314
reset,0.00955050504128314
resistance,0.00955050504128314
interestingly,0.00955050504128314
compartments,0.00955050504128314
compound,0.00955050504128314
supporting,0.00955050504128314
clones,0.00955050504128314
cni,0.00955050504128314
colchicine,0.00955050504128314
colony,0.00955050504128314
changed,0.00955050504128314
checkpoints,0.00955050504128314
itac,0.00955050504128314
kappa,0.00955050504128314
prevents,0.00955050504128314
pro,0.00955050504128314
dqb1,0.00955050504128314
dramatic,0.00955050504128314
drastically,0.00955050504128314
laboratories,0.00955050504128314
lam,0.00955050504128314
largely,0.00955050504128314
pnh,0.00955050504128314
suppression,0.00955050504128314
survivals,0.00955050504128314
susceptibility,0.00955050504128314
cyp,0.00955050504128314
cytochromes,0.00955050504128314
cytopathogenic,0.00955050504128314
decade,0.00955050504128314
decisive,0.00955050504128314
selecting,0.00955050504128314
proved,0.00955050504128314
herpes,0.00955050504128314
displaying,0.00955050504128314
dividing,0.00955050504128314
dme,0.00955050504128314
guided,0.00955050504128314
gupta,0.00955050504128314
gvl,0.00955050504128314
haplomudelederly,0.00955050504128314
capability,0.00955050504128314
precipitating,0.00955050504128314
preliminary,0.00955050504128314
prescribing,0.00955050504128314
clinicaltrials,0.00955050504128314
luznik,0.00955050504128314
lymphomas,0.00955050504128314
lytic,0.00955050504128314
leaving,0.00955050504128314
led,0.00955050504128314
caucasian,0.00955050504128314
cb,0.00955050504128314
blocking,0.00955050504128314
br3,0.00955050504128314
burden,0.00955050504128314
busulfan,0.00955050504128314
ligands,0.00955050504128314
knowing,0.00955050504128314
authors,0.00955050504128314
autoreactive,0.00955050504128314
bashey,0.00955050504128314
phlebotomies,0.00955050504128314
plasmablasts,0.00955050504128314
play,0.00955050504128314
plays,0.00955050504128314
limiting,0.00955050504128314
location,0.00955050504128314
calcineurin,0.00955050504128314
calmettes,0.00955050504128314
therapeutically,0.00955050504128314
thoroughly,0.00955050504128314
evasion,0.00955050504128314
exists,0.00955050504128314
expansion,0.00955050504128314
engaged,0.00955050504128314
rise,0.00955050504128314
rondelli,0.00955050504128314
rr,0.00955050504128314
devastating,0.00955050504128314
develops,0.00955050504128314
psychiatry,0.00955050504128314
pure,0.00955050504128314
granulocyte,0.00955050504128314
easier,0.00955050504128314
cryoglobulin,0.00955050504128314
image,0.00955050504128314
hodgkins,0.00955050504128314
hyperacute,0.00955050504128314
promoted,0.00955050504128314
depends,0.00955050504128314
enhances,0.00955050504128314
epitopes,0.00955050504128314
eta,0.00955050504128314
removes,0.00955050504128314
furthermore,0.00955050504128314
asthenia,0.00955050504128314
timeframe,0.00955050504128314
blaise,0.00955050504128314
personalized,0.00955050504128314
meaningful,0.00955050504128314
mechanisms,0.00955050504128314
transient,0.00955050504128314
mediated,0.00955050504128314
merkel,0.00955050504128314
metabolizing,0.00955050504128314
applying,0.00955050504128314
arising,0.00955050504128314
transplants,0.00955050504128314
transporter,0.00955050504128314
myelodysplastic,0.00955050504128314
microenvironment,0.00955050504128314
molecules,0.00955050504128314
antidepressants,0.00955050504128314
antiinflammatory,0.00955050504128314
antitumor,0.00955050504128314
anymore,0.00955050504128314
pathogenesis,0.00955050504128314
pathogens,0.00955050504128314
pathophysiology,0.00955050504128314
patriarca,0.00955050504128314
accuracy,0.00955050504128314
underwent,0.00955050504128314
nineteen,0.00955050504128314
origin,0.00955050504128314
overproduction,0.00955050504128314
p450,0.00955050504128314
extensively,0.00955050504128314
relapsed,0.00955050504128314
relatively,0.00955050504128314
etanercept,0.00955050504128314
europa,0.00955050504128314
045,0.00955050504128314
accelerate,0.00955050504128314
difficile,0.00955050504128314
difficult,0.00955050504128314
secreted,0.00955050504128314
defective,0.00955050504128314
paoli,0.00955050504128314
mucosal,0.00955050504128314
transporters,0.00955050504128314
tribeca,0.00955050504128314
affecting,0.00955050504128314
affective,0.00955050504128314
aggressive,0.00955050504128314
aim,0.00955050504128314
transplantations,0.00955050504128314
82,0.00955050504128314
venlafaxine,0.00955050504128314
vary,0.00955050504128314
workshop,0.00955050504128314
younger,0.00955050504128314
warranted,0.00955050504128314
neoplastic,0.00955050504128314
83,0.00955050504128314
2124,0.00955050504128314
uvb,0.00955050504128314
valuable,0.00955050504128314
valid,0.00955050504128314
58,0.00955050504128314
2004,0.00955050504128314
various,0.008241302241855509
unaffected,0.008241302241855509
achieving,0.008241302241855509
adhesive,0.008241302241855509
pancytopenia,0.008241302241855509
neuro,0.008241302241855509
neoplasm,0.008241302241855509
natural,0.008241302241855509
tumour,0.008241302241855509
aimed,0.008241302241855509
agreement,0.008241302241855509
agent,0.008241302241855509
alteration,0.008241302241855509
alloreactive,0.008241302241855509
apparent,0.008241302241855509
aplasia,0.008241302241855509
antigens,0.008241302241855509
transfused,0.008241302241855509
topical,0.008241302241855509
assessing,0.008241302241855509
appeared,0.008241302241855509
background,0.008241302241855509
availability,0.008241302241855509
auto,0.008241302241855509
md,0.008241302241855509
persistence,0.008241302241855509
periods,0.008241302241855509
performing,0.008241302241855509
native,0.008241302241855509
mucosa,0.008241302241855509
benefits,0.008241302241855509
brands,0.008241302241855509
bowel,0.008241302241855509
cataract,0.008241302241855509
cardio,0.008241302241855509
pleural,0.008241302241855509
physicians,0.008241302241855509
masquerade,0.008241302241855509
synthetic,0.008241302241855509
surveillance,0.008241302241855509
clonal,0.008241302241855509
classified,0.008241302241855509
classical,0.008241302241855509
suggesting,0.008241302241855509
suggested,0.008241302241855509
subpopulations,0.008241302241855509
composed,0.008241302241855509
components,0.008241302241855509
complication,0.008241302241855509
commonly,0.008241302241855509
combine,0.008241302241855509
species,0.008241302241855509
concerns,0.008241302241855509
concentrations,0.008241302241855509
countries,0.008241302241855509
correlate,0.008241302241855509
possibly,0.008241302241855509
larger,0.008241302241855509
l2,0.008241302241855509
light,0.008241302241855509
ligand,0.008241302241855509
lymphoid,0.008241302241855509
contain,0.008241302241855509
sole,0.008241302241855509
simple,0.008241302241855509
crohns,0.008241302241855509
critical,0.008241302241855509
primarily,0.008241302241855509
involves,0.008241302241855509
showed,0.008241302241855509
cytopenia,0.008241302241855509
depressive,0.008241302241855509
dependent,0.008241302241855509
dependence,0.008241302241855509
scheme,0.008241302241855509
digital,0.008241302241855509
reticulocytes,0.008241302241855509
donation,0.008241302241855509
distinct,0.008241302241855509
disappearance,0.008241302241855509
dropping,0.008241302241855509
effusion,0.008241302241855509
effectively,0.008241302241855509
immunosuppressives,0.008241302241855509
process,0.008241302241855509
investigated,0.008241302241855509
ebmt,0.008241302241855509
respect,0.008241302241855509
escalation,0.008241302241855509
erythematosus,0.008241302241855509
episode,0.008241302241855509
entering,0.008241302241855509
expect,0.008241302241855509
eventually,0.008241302241855509
eu,0.008241302241855509
reliability,0.008241302241855509
relapsing,0.008241302241855509
regulation,0.008241302241855509
extreme,0.008241302241855509
explore,0.008241302241855509
experts,0.008241302241855509
proteasome,0.008241302241855509
proposal,0.008241302241855509
properly,0.008241302241855509
ib,0.008241302241855509
regarding,0.008241302241855509
recruiting,0.008241302241855509
fibrosis,0.008241302241855509
fatal,0.008241302241855509
familial,0.008241302241855509
reasonable,0.008241302241855509
glaucoma,0.008241302241855509
gives,0.008241302241855509
haplotype,0.008241302241855509
haematological,0.008241302241855509
guide,0.008241302241855509
rarely,0.008241302241855509
pyelonephritis,0.008241302241855509
held,0.008241302241855509
harvest,0.008241302241855509
48h,0.008241302241855509
44,0.008241302241855509
34,0.008241302241855509
2018,0.008241302241855509
91,0.008241302241855509
useful,0.008241302241855509
noted,0.008241302241855509
noninfectious,0.008241302241855509
open,0.008241302241855509
occlusion,0.008241302241855509
2000,0.008241302241855509
mononuclear,0.007225805657153475
paper,0.007225805657153475
panel,0.007225805657153475
numbers,0.007225805657153475
forms,0.007225805657153475
frequently,0.007225805657153475
hepatic,0.007225805657153475
hhv8,0.007225805657153475
purpose,0.007225805657153475
affect,0.007225805657153475
glucocorticoids,0.007225805657153475
recherche,0.007225805657153475
reaches,0.007225805657153475
85,0.007225805657153475
recipients,0.007225805657153475
examinations,0.007225805657153475
average,0.007225805657153475
eltrombopag,0.007225805657153475
arthritis,0.007225805657153475
appears,0.007225805657153475
attenuated,0.007225805657153475
apn,0.007225805657153475
earlier,0.007225805657153475
disorder,0.007225805657153475
direct,0.007225805657153475
blind,0.007225805657153475
independence,0.007225805657153475
investigating,0.007225805657153475
easily,0.007225805657153475
safe,0.007225805657153475
rifaximin,0.007225805657153475
immunization,0.007225805657153475
infiltration,0.007225805657153475
relationship,0.007225805657153475
experience,0.007225805657153475
recruited,0.007225805657153475
recovery,0.007225805657153475
eradication,0.007225805657153475
immunodeficiency,0.007225805657153475
hospitalier,0.007225805657153475
immunotherapy,0.007225805657153475
persistent,0.007225805657153475
clinique,0.007225805657153475
sub,0.007225805657153475
success,0.007225805657153475
ciprofloxacin,0.007225805657153475
pharmacodynamics,0.007225805657153475
pharmacokinetics,0.007225805657153475
plasmapheresis,0.007225805657153475
platform,0.007225805657153475
male,0.007225805657153475
marker,0.007225805657153475
thymocyte,0.007225805657153475
murine,0.007225805657153475
mild,0.007225805657153475
metastatic,0.007225805657153475
myeloid,0.007225805657153475
targeted,0.007225805657153475
brochure,0.007225805657153475
bilateral,0.007225805657153475
beneficial,0.007225805657153475
61,0.007225805657153475
world,0.007225805657153475
whichever,0.007225805657153475
59,0.007225805657153475
54,0.007225805657153475
mscs,0.007225805657153475
action,0.007225805657153475
advanced,0.007225805657153475
ab,0.007225805657153475
adenocarcinoma,0.007225805657153475
abnormal,0.007225805657153475
undergoing,0.007225805657153475
block,0.007225805657153475
legal,0.007225805657153475
lead,0.007225805657153475
social,0.007225805657153475
similar,0.007225805657153475
ktr,0.007225805657153475
large,0.007225805657153475
label,0.007225805657153475
prescribed,0.007225805657153475
intolerance,0.007225805657153475
intervention,0.007225805657153475
involve,0.007225805657153475
joint,0.007225805657153475
cyclosporine,0.007225805657153475
sustained,0.007225805657153475
cd8,0.007225805657153475
lack,0.007225805657153475
schedule,0.007225805657153475
segment,0.007225805657153475
individuals,0.006396084533009886
deterioration,0.006396084533009886
require,0.006396084533009886
detailed,0.006396084533009886
determine,0.006396084533009886
determined,0.006396084533009886
endoscopic,0.006396084533009886
gene,0.006396084533009886
hemolytic,0.006396084533009886
hematological,0.006396084533009886
real,0.006396084533009886
difference,0.006396084533009886
respond,0.006396084533009886
needs,0.006396084533009886
2003,0.006396084533009886
occurs,0.006396084533009886
adaptive,0.006396084533009886
account,0.006396084533009886
activation,0.006396084533009886
180,0.006396084533009886
49,0.006396084533009886
measured,0.006396084533009886
mesylate,0.006396084533009886
medicine,0.006396084533009886
class,0.006396084533009886
cohorts,0.006396084533009886
binding,0.006396084533009886
act,0.006396084533009886
blinded,0.006396084533009886
01,0.006396084533009886
occurring,0.006396084533009886
cure,0.006396084533009886
target,0.006396084533009886
consecutive,0.006396084533009886
regression,0.006396084533009886
proposed,0.006396084533009886
eyes,0.006396084533009886
relapses,0.006396084533009886
institut,0.006396084533009886
programme,0.006396084533009886
extra,0.006396084533009886
attributed,0.006396084533009886
tolerated,0.006396084533009886
discontinued,0.006396084533009886
injections,0.006396084533009886
beginning,0.006396084533009886
hypertension,0.006396084533009886
immunological,0.006396084533009886
immunogenicity,0.006396084533009886
flare,0.006396084533009886
entry,0.006396084533009886
product,0.006396084533009886
pan,0.006396084533009886
observations,0.006396084533009886
grafalon,0.006396084533009886
functions,0.006396084533009886
future,0.006396084533009886
provide,0.006396084533009886
allows,0.006396084533009886
answer,0.006396084533009886
pulmonary,0.006396084533009886
unacceptable,0.006396084533009886
identified,0.006396084533009886
genetic,0.006396084533009886
hgf,0.006396084533009886
kidney,0.006396084533009886
practice,0.006396084533009886
conventional,0.006396084533009886
pressure,0.006396084533009886
consumption,0.006396084533009886
cytokine,0.006396084533009886
decreased,0.006396084533009886
scores,0.006396084533009886
described,0.006396084533009886
damage,0.006396084533009886
bleeding,0.006396084533009886
particular,0.006396084533009886
cytokines,0.006396084533009886
lymphocytes,0.006396084533009886
center,0.006396084533009886
injected,0.005694565318261649
evaluated,0.005694565318261649
responses,0.005694565318261649
allow,0.005694565318261649
factor,0.005694565318261649
proportion,0.005694565318261649
recommended,0.005694565318261649
refer,0.005694565318261649
hospitalizations,0.005694565318261649
radiation,0.005694565318261649
33,0.005694565318261649
36,0.005694565318261649
25,0.005694565318261649
given,0.005694565318261649
neutrophil,0.005694565318261649
neutrophils,0.005694565318261649
heart,0.005694565318261649
organ,0.005694565318261649
regulatory,0.005694565318261649
release,0.005694565318261649
principal,0.005694565318261649
presented,0.005694565318261649
investigator,0.005694565318261649
investigators,0.005694565318261649
interaction,0.005694565318261649
minimal,0.005694565318261649
decrease,0.005694565318261649
mixed,0.005694565318261649
selection,0.005694565318261649
scale,0.005694565318261649
symptoms,0.005694565318261649
syndromes,0.005694565318261649
taken,0.005694565318261649
counts,0.005694565318261649
concerning,0.005694565318261649
corticosteroids,0.005694565318261649
completed,0.005694565318261649
concomitant,0.005694565318261649
sites,0.005694565318261649
skin,0.005694565318261649
sle,0.005694565318261649
single,0.005694565318261649
cutaneous,0.005694565318261649
composite,0.005694565318261649
covid,0.005694565318261649
course,0.005694565318261649
present,0.005694565318261649
testing,0.005694565318261649
thrombosis,0.005694565318261649
therapies,0.005694565318261649
liver,0.005694565318261649
classic,0.005694565318261649
place,0.005694565318261649
camostat,0.005694565318261649
cause,0.005694565318261649
uninjected,0.005694565318261649
notably,0.005694565318261649
normal,0.005694565318261649
nk,0.005694565318261649
onset,0.005694565318261649
opinion,0.005694565318261649
occurrence,0.005694565318261649
55,0.005086881733582255
additional,0.005086881733582255
adverse,0.005086881733582255
multiple,0.005086881733582255
cardiac,0.005086881733582255
macular,0.005086881733582255
placebo,0.005086881733582255
characteristics,0.005086881733582255
chimerism,0.005086881733582255
corticosteroid,0.005086881733582255
count,0.005086881733582255
step,0.005086881733582255
current,0.005086881733582255
signs,0.005086881733582255
lesions,0.005086881733582255
previously,0.005086881733582255
interval,0.005086881733582255
samples,0.005086881733582255
date,0.005086881733582255
decision,0.005086881733582255
sensitivity,0.005086881733582255
modified,0.005086881733582255
edema,0.005086881733582255
doses,0.005086881733582255
duration,0.005086881733582255
intravenous,0.005086881733582255
injection,0.005086881733582255
independent,0.005086881733582255
progression,0.005086881733582255
et,0.005086881733582255
includes,0.005086881733582255
greater,0.005086881733582255
groups,0.005086881733582255
followed,0.005086881733582255
validated,0.005086881733582255
quality,0.005086881733582255
amplification,0.005086881733582255
order,0.005086881733582255
